Statutory Rules 1990 No. 3431
–––––––
Health Insurance (1990-91 Pathology
Services Table) Regulations
I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the Health Insurance Act 1973.
Dated 25 October 1990.
BILL HAYDEN
Governor-General
By His Excellency’s Command,
B. HOWE
Minister of State for Community Services
and Health
–––––––––
Citation
1. These Regulations may be cited as the Health Insurance (1990-91 Pathology Services Table) Regulations.
Commencement
2. These Regulations commence on 1 November 1990.
Repeal
3. Statutory Rules 1990 No. 312 are repealed.
Pathology services table
4. The following table of pathology services is prescribed for the purposes of subsection 4a (2) of the Health Insurance Act 1973:
PATHOLOGY SERVICES TABLE
RULES OF INTERPRETATION
1. In this table:
“Division” means a Division of the list of services and fees in this table;
“item” means an item in that list;
“recognised pathologist” means a medical practitioner who under a determination under section 61, is recognised for the purposes of this Act as a specialist in the specialty of pathology.
2. If an item includes the symbol “(SP)”, the item relates to a pathology service when rendered by or on behalf of an approved pathology practitioner who is a recognised pathologist other than a pathology service:
(a) rendered following a request made in the course of the provision of an out-patient service at a recognised hospital; or
(b) rendered following a request made in respect of a person who was, at the time when the request was made, a private patient in a recognised hospital; or
(c) in the rendering of which:
(i) any pathology equipment of a recognised hospital, or a laboratory included in a prescribed class of laboratories, is used; or
(ii) any member of the staff of a recognised hospital, or a laboratory included in a prescribed class of laboratories, participates in the course of that member’s employment with that hospital or laboratory.
3. If an item includes the symbol “(OP)”, the item is taken to relate to a pathology service other than a pathology service:
(a) to which an item that includes the symbol “(SP)” relates; or
(b) to which subsection 16a (7) applies.
4. For the purposes of rules 2 and 3, each of the following classes of laboratories is a prescribed class of laboratories:
(a) laboratories operated by the Commonwealth;
(b) laboratories operated by a State or an authority of a State;
(c) laboratories operated by the Northern Territory;
(d) laboratories operated by the Australian Capital Territory;
(e) laboratories operated by an Australian tertiary education institution.
5. 2 or more pathology services rendered following 2 or more requests are taken to have been rendered following a single request if:
(a) each pathology service is rendered to the same person; and
(b) each pathology service is listed in the same item; and
(c) the determinations of the necessity for the pathology services were made on the same day.
6. In rule 5, “service” includes an assay, estimation and test.
7. A reference in these rules to a request made to an approved pathology practitioner includes a reference to a request that is taken for the purposes of section 16a, to have been made to that approved pathology practitioner.
8. If:
(a) a pathology service (in this rule called the “first pathology service”) is rendered following a request; and
(b) an item of the table applies to that pathology service; and
(c) another pathology service (in this rule called the “second pathology service”) is rendered following the request; and
(d) the second pathology service is of a kind referred to in the item referred to in paragraph (b);
the second pathology service is treated as if it were subsumed within the first pathology service.
Example: Dr Proctor requests an extended blood grouping test (covered by item 1192) and the test includes a basic blood grouping test (covered by item 1187). Item 1187 is referred to in item 1192. Benefit is payble under item 1192 for the extended blood grouping test but benefit is not payable separately under item 1187 for the basic blood grouping test.
9. For the purposes of Division 1:
(a) if pathology services of a kind referred to in item 1187, 1188, 1192 or 1193 are rendered to a person during a period of hospitalisation, the item applies only to the first pathology service of that kind rendered to the person during that person’s hospitalisation; and
(b) tests performed on material stored from a previous patient episode (except tests specified in item 1198 of 1199) in response to a later request are treated as being part or that previous patient episode if the second request is made within 14 days of that previous patient episode.
10. For the purposes of Division 2:
(a) if a pathology service involving the measurement of any substance in urine requires a 24 hour urine collection or
calculation of a substance/creatinine ratio, that pathology service is treated as including any estimation of creatinine in other fluids necessary for calculation; and
(b) tests performed on material stored from a previous patient episode in response to a subsequent request are treated as being part of that previous patient episode if the second request occurs within 14 days of that previous patient episode.
11. For the purposes of Division 3:
(a) serial examinations or cultures means examinations or cultures requested on the 1 occasion regardless of whether the materials are received on different days by the approved pathology practitioner and regardless of whether the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and
(b) tests performed on material that has been stored from a previous patient episode in response to a later request are treated as being part of that previous patient episode if the further request occurs within 14 days of that previous patient episode.
12. For the purposes of Division 4:
(a) tests performed on material that has been stored from a previous patient episode in response to a later request are treated as being part of that previous patient episode if the further request occurs within 14 days of that previous patient episode; and
(b) in items 2271, 2274, 2275, 2276, 2277, 2278, 2279 and 2280, the estimation of a single antibody includes qualitative and quantitative assays for that antibody.
13. For the purposes of Division 5:
(a) “biopsy material” means all tissue received by the approved pathology practitioner from any operation or group of operations performed on a patient at the same time other than a bone marrow biopsy; and
(b) if a pathology service relating to the examination of biopsy material is rendered under an item set out in Division 5 in circumstances where a further pathology service specified in an item in Division 5 is rendered also in relation to that biopsy material all those pathology services are treated as 1 pathology service under the same item appropriate to the pathology services provided.
14. For the purposes of Division 6, “serial examinations” means examinations requested on the same occasion regardless of whether the materials are received on different days by the approved pathology practitioner and regardless of whether the examinations were requested on 1 or more request forms by the treating practitioner.
15. If in these Rules provision is made for 2 or more pathology services to be treated as 1 pathology service, a reference to an appropriate item is a reference to the item that incorporates whichever of the symbols “(SP)” or “(OP)” is relevant to the rendering of that pathology service.
16. The lists of abbreviations at the end of the table are provided to allow users of the table to identify and refer to particular pathology services, or groups of pathology services, more accurately and efficiently.
SERVICES AND FEES
| Item | Pathology service | Fee |
| | Division 1—Haematology | $ |
| 1163 | Blood count consisting of erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, reticulocyte count—1 or 2 procedures (SP) | 7.80 |
| 1164 | Blood count consisting of erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, reticulocyte count—1 or 2 procedures (OP) | 5.90 |
| 1168 | 3 or more procedures to which item 1163 applies, including any calculation or measurement of erythrocyte or other indices (SP) | 10.60 |
| 1169 | 3 or more procedures to which item 1164 applies, including any calculation or measurement of erythrocyte or other indices (OP) | 7.95 |
| 1170 | Examination of blood film, with or without differential cell count, or differential cell count with or without examination of blood film, and if performed, any of these additional services—Direct Coombs test, tests for heterophile antibodies, cold agglutinins, examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron, or examination of a blood film with alpha-naphthyl acetate esterase, choloroacetate esterase, neutrophil alkaline phosphotase, nitro blue tetrazolium, periodic acid Schiff, Sudan Black stains, or Kleihauer test for HbF on blood film, including any services soecified in item 1419 (SP) | 14.00 |
| 1171 | Examination of blood film, with or without differential cell count, or differential cell count with or without examination of blood film, and if performed, any of these additional services—Direct Coombs test, tests for heterophile antibodies, cold agglutinins, examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron, or examination of a blood film with alpha-naphthyl acetate esterase, choloroacetate esterase, neutrophil alkaline phosphotase, nitro blue tetrazolium, periodic acid Schiff, Sudan Black stains, or Kleihauer test for HbF on blood film, inlcuding any services soecified in item 1420 (OP) | 10.45 |
| 1172 | Full blood examination consisting of items 1168 and 1170 (SP) | 24.50 |
| Item | Pathology service | Fee |
| | | $ |
| 1173 | Full blood examination consisting of items 1169 and 1171 (OP) | 18.20 |
| 1176 | Erythrocytes, qualitative or quantitative assessment of haemolysis or metabolic enzymes by—erythrocyte autohaemolysis test, erythrocyte fragility test, sugar water test, erythrocyte metabolic enzyme test, heat denaturation test, isopropanol precipitation test, acid haemolysis test, and quantitation of muramidase in serum or urine—1 or more procedures (SP) | 32.00 |
| 1177 | Erythrocytes, qualitative or quantitative assessment of haemolysis or metabolic enzymes by—erythrocyte autohaemolysis test, erythrocyte fragility test, sugar water test, erythrocyte metabolic enzyme test, heat denaturation test, isopropanol precipitation test, acid haemolysis test, and quantitation of muramidase in serum or urine—1 or more procedures (OP) | 24.20 |
| 1179 | Tests for the diagnosis of haemoglobinopathy consisting of haemoglobin electrophoresis and 2 of the following— examination for HbH, quantitation of HbA2 or HbF, including any service specified in item 1163, 1168, 1170 or 1172 (SP) | 50.00 |
| 1180 | Tests for the diagnosis of haemoglobinopathy consisting of haemoglobin electrophoresis and 2 of the following— examination for HbH, quantitation of HbA2 or HbF, including any service specified in item 1164, 1169, 1171 or 1173 (OP) | 37.65 |
| 1181 | Histopathological examination of sections of bone marrow trephine biopsy including where indicated, examination of marrow smears and any special stains and immunochemical techniques, including any service specified in item 1163. 1168. 1170. 1172 or 1183 (SP) | 154.00 |
| 1182 | Histopathological examination of sections of bone marrow trephine biopsy including where indicated, examination of marrow smears and any special stains and immunochemical techniques, including any service specified in item 1164, 1169, 1171, 1173 or 1184 (OP) | 115.55 |
| 1183 | Bone marrow examination of aspirated material including any special stains, immuno-chemical techniques and clot sections where necessary, including any service specified in item 1163, 1168, 1170 or 1172 (SP) | 112.00 |
| 1184 | Bone marrow examination of aspirated material including any special stains, immuno-chemical techniques and clot sections where necessary, including any service specified in item 1164, 1169, 1171 or 1173 (OP) | 83.90 |
| 1187 | Blood grouping, including back-grouping when performed—ABO and Rh (D antigen) (SP) | 13.60 |
| 1188 | Blood grouping, including back-grouping when performed—ABO and Rh (D antigen) (OP) | 10.15 |
| 1192 | Blood grouping—Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system—one or more systems, including any service specified in item 1187 (SP) | 27.00 |
| | | | |
| Item | Pathology service | Fee |
| | | $ |
| 1193 | Blood grouping—Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system—one or more systems, including any service specified in item 1188 (OP) | 20.25 |
| 1196 | Blood grouping, including back-grouping when performed, and examination of serum for Rh and other blood group antibodies, including identification and quantitative estimation of any antibodies detected, and including any service specified in item 1163, 1168, 1170 or 1172 (SP) | 50.00 |
| 1197 | Blood grouping, including back-grouping when performed, and examination of serum for Rh and other blood group antibodies, including identification and quantitative estimation of any antibodies detected, and including any service specified in item 1164, 1169, 1171 or 1173 (OP) | 37.65 |
| 1198 | Compatibility testing, including all necessary grouping checks of patient and donor, examination for antibodies, identification and, if necessary, quantitative estimation of any antibodies detected and any service specified in item 1163, 1168, 1170, 1172, 1187 or 1196 including all testing performed on any 1 day (SP) | 122.00 |
| 1199 | Compatibility testing, including all necessary grouping checks of patient and donor, examination for antibodies, identification and, if necessary, quantitative estimation of any antibodies detected and any service specified in item 1164, 1169, 1171, 1173, 1188 or 1197 including all testing performed on any 1 day (OP) | 91.80 |
| 1417 | Examination of serum for blood group antibodies including identification and, if necessary, quantitative estimation of any antibodies detected (SP) | 22.00 |
| 1418 | Examination of serum for blood group antibodies including identification and, if necessary, quantitative estimation of any antibodies detected (OP) | 16.65 |
| 1419 | Direct Coombs test, qualitative or quantitative test for cold agglutinins, or heterophile antibodies, qualitative spectroscopic examination of blood for abnormal haemoglobins, qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test) including service specified in item 1170 or 1172—1 or more tests (SP) | 12.20 |
| 1420 | Direct Coombs test, qualitative or quantitative test for cold agglutinins, or heterophile antibodies, qualitative spectroscopic examination of blood for abnormal haemoglobins, qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test) including service specified in item 1171 or 1173—1 or more tests (OP) | 9.20 |
| Item | Pathology service | Fee |
| | | $ |
| 1521 | Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of—fibrinogen degradation products, fibrin monomer or D-dimer—1 estimation (SP) | 16.80 |
| 1522 | Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of—fibrinogen degradation products, fibrin monomer or D-dimer—1 estimation (OP) | 12.70 |
| 1523 | 2 estimations specified in item 1521 (SP) | 22.00 |
| 1524 | 2 estimations specified in item 1522 (OP) | 16.65 |
| 1525 | 3 estimations specified in item 1521 (SP) | 28.00 |
| 1526 | 3 estimations specified in item 1522 (OP) | 21.00 |
| 1527 | 4 or more estimations specified in item 1521 (SP) | 33.00 |
| 1528 | 4 or more estimations specified m item 1522 (OP) | 25.00 |
| 1531 | Quantitative assay, by 1 or more techniques, of plasminogen, antithrombin III, Protein C, Protein S, heparin co-factor II, Euglobulin clot lysis time and test for lupus anticoagulant—1 estimation (SP) | 33.00 |
| 1532 | Quantitative assay, by 1 or more techniques, of plasminogen, antithrombin III, Protein C, Protein S, heparin co-factor II, Euglobulin clot lysis time and test for lupus anticoagulant—1 estimation (OP) | 25.00 |
| 1533 | 4 or more estimations specified in item 1531 (SP) | 106.00 |
| 1534 | 4 or more estimations specified in item 1532 (OP) | 79.15 |
| 1535 | Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance—1 or more estimations (SP) | 66.00 |
| 1538 | Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance—1 or more estimations (OP) | 49.85 |
| 1539 | Heparin assay, only when monitoring a patient on subcutaneous heparin or low molecular weight heparin— 1 or more estimations (SP) | 44.50 |
| 1540 | Heparin assay, only when monitoring a patient on subcutaneous heparin or low molecular weight heparin— 1 or more estimations (OP) | 33.25 |
| 1541 | Quantitative assay of Von Willebrand’s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, Passovy factor— 1 estimation (SP) | 44.50 |
| 1542 | Quantitative assay of Von Willebrand s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, Passovy factor— 1 estimation (OP) | 33.25 |
| 1543 | 2 estimations as specified in item 1541 (SP) | 66.00 |
| Item | Pathology service | Fee |
| | | $ |
| 1544 | 2 estimations as specified in item 1542 (OP) | 49.85 |
| 1550 | 3 or more estimations as specified in item 1541 (SP) | 83.00 |
| 1551 | 3 or more estimations as specified in item 1542 (OP) | 62.55 |
| | Division 2—Chemical Pathology | |
| 1558 | Quantitative estimation in serum, plasma, urine or any other body fluid, by any method except by reagent strip with or without reflectance meter or electrophoresis of—alanine amino-transferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total and any fractions), calcium (total, dialysed or ionized), chloride, cholesterol, creatine kinase, creatine kinase isoenzymes (when not performed as specified in item 1734), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, triglycerides, urate, urea—1 estimation (SP) | 14.00 |
| 1559 | Quantitative estimation in serum, plasma, urine or any other body fluid, by any method except by reagent strip with or without reflectance meter or electrophoresis of—alanine amino-transferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total and any fractions), calcium (total, dialysed or ionized), chloride, cholesterol, creatine kinase, creatine kinase isoenzymes (when not performed as specified in item 1735), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, triglycerides, urate, urea—1 estimation (OP) | 10.45 |
| 1560 | 2 estimations specified in item 1558 (SP) | 16.80 |
| 1561 | 2 estimations specified in item 1559 (OP) | 12.70 |
| 1562 | 3 estimations specified in item 1558 (SP) | 19.60 |
| 1563 | 3 estimations specified in item 1559 (OP) | 14.75 |
| 1564 | 4 estimations specified in item 1558 (SP) | 22.00 |
| 1565 | 4 estimations specified in item 1559 (OP) | 16.65 |
| 1569 | 5 estimations specified in item 1558 (SP) | 25.00 |
| 1570 | 5 estimations specified in item 1559 (OP) | 18.65 |
| 1571 | 6 or more estimations specified in item 1558 (SP) | 28.00 |
| 1572 | 6 or more estimations specified in item 1559 (OP) | 21.00 |
| 1575 | Qualitative estimation by any method, except by reagent strip or dip-stick of the following urine constituents— bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen or pH measurement of body fluids other than urine (excepting urine acidification test), or cryoglobulins or cryofibrinogen in plasma—1 or more estimations (SP) | 13.20 |
| Item | Pathology service | Fee |
| | | $ |
| 1576 | Qualitative estimation by any method, except by reagent strip or dip-stick of the following urine constituents— bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen or pH measurement of body fluids other than urine (excepting urine acidification test), or cryoglobulins or cryofibrinogen in plasma—1 or more estimations (OP) | 10.00 |
| 1577 | Qualitative estimation by any method except by reagent strip or dip-stick of the following faecal constituents— haemoglobin, porphyrins, reducing substances—each estimation, to a maximum of 3 estimations, taken on separate days (SP) | 8.90 |
| 1578 | Qualitative estimation by any method except by reagent strip or dip-stick of the following faecal constituents— haemoglobin, porphyrins, reducing substances—each estimation, to a maximum of 3 estimations, taken on separate days (OP) | 6.65 |
| 1579 | Immunological tests for human haemoglobin in faeces performed in any 28 day period, including chemical test if performed—1 estimation (SP) | 16.80 |
| 1580 | Immunological tests for human haemoglobin in faeces performed in any 28 day period, including chemical test if performed—1 estimation (OP) | 12.70 |
| 1581 | 2 or more estimations specified in item 1579 (SP) | 38.50 |
| 1582 | 2 or more estimations specified in item 1580 (OP) | 28.95 |
| 1583 | Osmolality, estimation by osmometer, in serum or in urine—1 or more estimations (SP) | 33.00 |
| 1584 | Osmolality, estimation by osmometer, in serum or in urine—1 or more estimations (OP) | 25.00 |
| 1590 | Quantitative estimation of blood gases including tests performed from—pO2, oxygen saturation, pCO2, bicarbonate, pH, and any other measurement (e.g. haemoglobin, potassium) or calculation performed on the same specimen—1 or more estimation on 1 specimen (SP) | 45.50 |
| 1591 | Quantitative estimation of blood gases including tests performed from—pO2, oxygen saturation, pCO2, bicarbonate, pH, and any other measurement (e.g. haemoglobin, potassium) or calculation performed on the same specimen—1 or more estimation on 1 specimen (OP) | 34.05 |
| 1592 | 1 or more estimations of blood gases as specified in item 1590 on 2 or more specimens within any 1 day (SP) | 56.00 |
| 1593 | 1 or more estimations of blood gases as specified in item 1591 on 2 or more specimens within any 1 day (OP) | 41.95 |
| 1595 | Calculus, analysis of 1 or more (SP) | 41.00 |
| 1596 | Calculus, analysis of 1 or more (OP) | 30.90 |
| Item | Pathology service | Fee |
| | | $ |
| 1598 | Drug or chemical assays—including all qualitative and quantitative tests on blood, urine or other body fluid for a drug or drugs of abuse, including illegal drugs and legally available drugs taken other than in appropriate dosage, ingested or absorbed toxic chemicals including any service specified in item 1712, 1714 or 1716, but excluding the surveillance of sports people and athletes for performance improving substances—1 or more assays (SP) | 56.00 |
| 1599 | Drug or chemical assays—including all qualitative and quantitative tests on blood, urine or other body fluid for a drug or drugs of abuse, including illegal drugs and legally available drugs taken other than in appropriate dosage, ingested or absorbed toxic chemicals including any service specified in item 1713, 1715 or 1717, but excluding the surveillance of sports people and athletes for performance improving substances—1 or more assays (OP) | 41.95 |
| 1627 | Drug assays—including all qualitative and quantitative estimations on blood, urine or other body fluid for a drug of abuse or a therapeutic drug on a sample collected from a patient participating in a drug abuse treatment programme, or being treated for drug effects or under a court order or parole board supervision, but excluding the detection of nicotine and metabolites in smoking withdrawal programmes—each assay to a maximum of 4 assays within any 28 day period (SP) | 28.00 |
| 1628 | Drug assays—including all qualitative and quantitative estimations on blood, urine or other body fluid for a drug of abuse or a therapeutic drug on a sample collected from a patient participating in a drug abuse treatment programme, or being treated for drug effects or under a court order or parole board supervision, but excluding the detection of nicotine and metabolites in smoking withdrawal programmes—each assay to a maximum of 4 assays within any 28 day period (OP) | 21.00 |
| 1712 | Drug assay—quantitative estimation on blood or other body fluid by any method of a drug being used therapeutically for the patient from whom the specimen was taken and not elsewhere specified in the Schedule— 1 estimation (SP) | 28.00 |
| 1713 | Drug assay—quantitative estimation on blood or other body fluid by any method of a drug being used therapeutically for the patient from whom the specimen was taken and not elsewhere specified in the Schedule— 1 estimation (OP) | 21.00 |
| 1714 | 2 estimations specified in item 1712 (SP) | 38.50 |
| 1715 | 2 estimations specified in item 1713 (OP) | 28.95 |
| 1716 | 3 or more estimations specified in item 1712 (SP) | 50.00 |
| 1717 | 3 or more estimations specified in item 1713 (OP) | 37.65 |
| Item | Pathology service | Fee | |
| | | $ | |
| 1726 | Amniotic fluid, spectrophotometric examination of, estimation of lecithin/sphingomyelin ratio, palmitic acid, phosphatidylglycerol or lamellar body phospholipid— 1 or more examinations or estimations (SP) | 44.50 | |
| 1727 | Amniotic fluid, spectrophotometric examination of, estimation of lecithin/sphingomyelin ratio, palmitic acid, phosphatidylglycerol or lamellar body phospholipid— 1 or more examinations or estimations (OP) | 33.25 | |
| 1734 | Electrophoresis, quantitative or qualitative of serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, or the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase or lipoprotein electrophoresis (only when the Cholesterol is >6.5mmol/l and Triglyceride >3.0 mmol/1 or in the diagnosis of types III and IV hyperlipidemia), including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity—1 examination to a maximum of 2 examinations in any 12 month period (SP) | 41.00 | |
|
|
|
|
|
|
|
|
| 1735 | Electrophoresis, quantitative or qualitative of serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, or the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase or lipoprotein electrophoresis (only when the Cholesterol is >6.5 mmol/1 and Triglyceride >3.0 mmol/1 or in the diagnosis of types III and IV hyperlipidemia), including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity—1 examination to a maximum of 2 examinations in any 12 month period (OP) | 30.90 | |
| 1736 | Electrophoresis, quantitative or qualitative of concurrently collected, or collected within a 28 day period, serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, including the preliminary quantitation of total protein, albumin and globulin, or of total relevant enzyme activity—2 or more examinations (SP) | 61.00 | |
|
|
|
|
|
| 1737 | Electrophoresis, quantitative or qualitative of concurrently collected, or collected within a 28 day period, serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, including the preliminary quantitation of total protein, albumin and globulin, or of total relevant enzyme activity—2 or more examinations (OP) | 45.90 | |
|
| Item | Pathology service | Fee |
| | | $ |
| 1738 | Alpha-feto protein, Alpha-1 antitrypsin, Alpha-2 macroglobulin, beta-2 microglobulin, C-l esterase inhibitor, Caeruloplasmin, Ferritin (unless specified in item 1752), Haptoglobins, Microalbumin (in proven diabetes mellitus), Prealbumin, Prostate Specific Antigen, Prostatic Acid Phosphatase, Transferrin (unless specified in item 1752) and, in the follow-up of proven malignancy, Mucin-like carcinoma associated antigen, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen, Carcinoembryonic antigen, Mammary serum antigen, Neuron specific enolase, SCC Related antigen, Thyroglobulin—quantitative estimation in serum, urine or other body fluid—1 estimation (SP) | 27.00 |
| 1739 | Alpha-feto protein, Alpha-1 antitrypsin, Alpha-2 macroglobulin, beta-2 microglobulin, C-l esterase inhibitor, Caeruloplasmin, Ferritin (unless specified in item 1753), Haptoglobins, Microalbumin (in proven diabetes mellitus), Prealbumin, Prostate Specific Antigen, Prostatic Acid Phosphatase, Transferrin (unless specified in item 1753) and, in the follow up of proven malignancy, Mucin-like carcinoma associated antigen, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen, Carcinoembryonic antigen, Mammary serum antigen, Neuron specific enolase, SCC Related antigen, Thyroglobulin—quantitative estimation in serum, urine or other body fluid—1 estimation (OP) | 20.25 |
| 1740 | 2 or more estimations specified in item 1738 (SP) | 50.00 |
| 1741 | 2 or more estimations specified in item 1739 (OP) | 37.65 |
| 1752 | Iron studies consisting of quantitative analysis of iron, | 53.00 |
| 1753 | transferrin or iron binding capacity and ferritin (SP) Iron studies consisting of quantitative analysis of iron, transferrin or iron binding capacity and ferritin (OP) | 39.60 |
| 1768 | Serum B12, serum folate—1 or more estimations within any 28 day period (SP) | 33.00 |
| 1769 | Serum B12, serum folate—1 or more estimations within any 28 day period (OP) | 25.00 |
| 1770 | Red cell folate and serum B12 and, if required, serum folate, to a maximum of 3 estimations in any 12 month period (SP) | 61 00 |
| 1771 | Red cell folate and serum B12 and, if required, serum folate, to a maximum of 3 estimations in any 12 month period (OP) | 45.40 |
| 1780 | Vitamins, quantitative estimation in blood, urine or other body fluid, by direct or indirect means, of Vitamins A, B1, B2, B3, B6, C, and E—1 or more estimations within any 6 month period (SP) | 41.00 |
| Item | Pathology service | Fee | |
| | | $ | |
| 1783 | Vitamins, quantitative estimation in blood, urine or other body fluid, by direct or indirect means, of Vitamins A, B1, B2, B3, B6, C, and E—1 or more estimations within any 6 month period (OP) | 30.90 | |
| 1786 | Vitamin D or D fractions—1 or more estimations (SP) | 41.00 | |
| 1787 | Vitamin D or D fractions—1 or more estimations (OP) | 30.90 | |
| 1791 | Acetoacetate, alcohol, aminoacids, ammonia, angiotensin converting enzyme, betahydroxybutyrate, cholinesterase, cystine (cysteine), total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, neonatal bilirubin (1 or more fractions), oxalate, pyruvate, serotonin, xylose, zinc—1 quantitative estimation (SP) | 33.00 | |
|
| 1792 | Acetoacetate, alcohol, aminoacids, ammonia, angiotensin converting enzyme, betahydroxybutyrate, cholinesterase, cystine (cysteine), total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, neonatal bilirubin (1 or more fractions), oxalate, pyruvate, serotonin, xylose, zinc—1 quantitative estimation (OP) | 25.00 | |
| 1795 | 2 or more estimations specified in item 1791 (SP) | 52.00 | |
| 1798 | 2 or more estimations specified in item 1792 (OP) | 39.20 | |
| 1871 | Aluminium, arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, strontium—in blood, urine or other body fluid or tissue—1 or more estimations within any 6 month period (SP) | 47.00 | |
| 1872 | Aluminium, arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, strontium—in blood, urine or other body fluid or tissue—1 or more estimations within any 6 month period (OP) | 35.25 | |
| 1895 | Blood lead estimation, other than for occupational health screening purposes, to a maximum of 3 estimations in any 6 month period—each estimation (SP) | 41.00 | |
| 1896 | Blood lead estimation, other than for occupational health screening purposes, to a maximum of 3 estimations in any 6 month period—each estimation (OP) | 30.90 | |
| 1959 | Porphyrins (1 or more fractions), Catecholamines (1 or more fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic Acid (HVA), Metanephrines, Methoxy Hydroxy Phenylethylene Glycol (MHPG), Phenyl Acetic Acid (PAA)—quantitative including any qualitative estimations—1 or more estimations (SP) | 54.00 | |
| 1960 | Porphyrins (1 or more fractions), Catecholamines (1 or more fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic Acid (HVA), Metanephrines, Methoxy Hydroxy Phenylethylene Glycol (MHPG), Phenyl Acetic Acid (PAA)—quantitative including any qualitative estimations—1 or more estimations (OP) | 40.40 | |
| 1963 | Faecal fat, Breath Hydrogen measurements m response to loading with disaccharides—1 or more quantitative estimations within any 28 day period (SP) | 54.00 | |
| Item | Pathology service | Fee |
| | | $ |
| 1964 | Faecal fat, Breath Hydrogen measurements in response to loading with disaccharides—1 or more quantitative estimations within any 28 day period (OP) | 40.40 |
| 1969 | Solid tissue or tissues excluding blood elements—assay of 1 or 2 enzymes (SP) | 54.00 |
| 1970 | Solid tissue or tissues excluding blood elements—assay of 1 or 2 enzymes (OP) | 40.40 |
| 1975 | Assay of 3 to 5 enzymes as specified in item 1969 (SP) | 100.00 |
| 1976 | Assay of 3 to 5 enzymes as specified in item 1970 (OP) | 75.20 |
| 1977 | Assay of 6 or more enzymes as specified in item 1969 (SP) | 132.00 |
| 1978 | Assay of 6 or more enzymes as specified in item 1970 (OP) | 99.70 |
| 1983 | Thyroid function tests, including thyrotrophin (TSH) and at least 1 or more of the following tests—free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin (SP) | 56.00 |
| 1984 | Thyroid function tests, including thyrotrophin (TSH) and at least 1 or more of the following tests—free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin (OP) | 41.95 |
| 1985 | Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and all necessary estimations of hormones (SP) | 66.00 |
| 1986 | Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and all necessary estimations of hormones (OP) | 49.85 |
| 1989 | Growth hormone suppression by glucose loading, Growth hormone stimulation by exercise, Dexamethasone suppression test, L-Dopa stimulation of growth hormone, where physically performed by a recognised pathologist—1 or more procedures (SP) | 15.80 |
| 1990 | Growth hormone suppression by glucose loading, Growth hormone stimulation by exercise, Dexamethasone suppression test, L-Dopa stimulation of growth hormone, where physically performed by a recognised pathologist—1 or more procedures (OP) | 11.90 |
| 1991 | Gonadotrophin releasing hormone stimulation test, Synacthen stimulation test, Glucagon stimulation test with C-peptide measurement, Pentagastrin stimulation of thyrocalcitonin release, Secretin stimulation of gastrin release, Insulin hypoglycaemia, Arginine infusion, where physically performed by a recognised pathologist—1 procedure (SP) | 53.00 |
| 1992 | Gonadotrophin releasing hormone stimulation test, Synacthen stimulation test, Glucagon stimulation test with C-peptide measurement, Pentagastrin stimulation of thyrocalcitonin release, Secretin stimulation of gastrin release, Insulin hypoglycaemia, Arginine infusion, where physically performed by a recognised pathologist—1 procedure (OP) | 39.60 |
| 1993 | 2 or more tests specified in item 1991 (SP) | 84.00 |
| 1994 | 2 or more tests specified in item 1992 (OP) | 63.30 |
| Item | Pathology service | Fee | |
| | | $ | |
| 2021 | Hormones and hormone binding proteins, quantitative estimation by any method of: ACTH, Aldosterone, Androstenedione, C-peptide, Calcitonin, Cortisol, Cyclic AMP, DHEAS, 11-Deoxycortisol, Dihydrotestosterone, FSH, Gastrin, Glucagon, Growth hormone, Human Placental Lactogen, Hydroxyprogesterone, Insulin, LH, Oestradiol, Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex hormone binding globulin, Somatomedin C(IgF1), free or total Testosterone, TSH (where not requested as part of a thyroid function test), Urine steroid fraction or fractions, Vasoactive intestinal peptide, Vasopressin (anti-diuretic hormone)—1 estimation (SP) | 38.50 | |
| 2024 | Hormones and hormone binding proteins, quantitative estimation by any method of: ACTH, Aldosterone, Androstenedione, C-peptide, Calcitonin, Cortisol, Cyclic AMP, DHEAS, 11-Deoxycortisol, Dihydrotestosterone, FSH, Gastrin, Glucagon, Growth hormone, Human Placental Lactogen, Hydroxyprogesterone, Insulin, LH, Oestradiol, Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex hormone binding globulin, Somatomedin C(IgF1), free or total Testosterone, TSH (where not requested as part of a thyroid function test), Urine steroid fraction or fractions, Vasoactive intestinal peptide, Vasopressin (anti-diuretic hormone)—1 estimation (OP) | 28.95 | |
| 2025 | 2 estimations specified in item 2021 (SP) | 61.00 | |
| 2026 | 2 estimations specified in item 2024 (OP) | 45.90 | |
| 2027 | 3 estimations specified in item 2021 (SP) | 77.00 | |
| 2028 | 3 estimations specified in item 2024 (OP) | 57.80 | |
| 2029 | 4 estimations specified in item 2021 (SP) | 94.00 | |
| 2030 | 4 estimations specified in item 2024 (OP) | 70.45 | |
| 2031 | 5 estimations specified in item 2021 (SP) | 106.00 | |
| 2032 | 5 estimations specified in item 2024 (OP) | 79.15 | |
| 2033 | 6 or more estimations specified in item 2021 (SP) | 118.00 | |
| 2034 | 6 or more estimations specified in item 2024 (OP) | 88.65 | |
| 2037 | Hormone receptor assay on proven primary breast carcinoma or subsequent lesion in the breast or metastasis from a breast carcinoma—1 or more assays (SP) | 108.00 | |
|
| 2038 | Hormone receptor assay on proven primary breast carcinoma or subsequent lesion in the breast or metastasis from a breast carcinoma—1 or more assays (OP) | 80.75 | |
| 2039 | HDL Cholesterol, estimation of, in patients with serum cholesterol >5.5mmol/l or those on prescribed lipid lowering drugs—each estimation to a maximum of 4 estimations in any 12 month period (SP) | 16.80 | |
| 2040 | HDL cholesterol, estimation of, in patients with serum cholesterol >5.5mmol/l or those on prescribed lipid lowering drugs—each estimation to a maximum of 4 estimations in any 12 month period (OP) | 12.70 | |
| Item | Pathology service | Fee |
| | | $ |
| 2043 | Glycosylated haemoglobin only when performed in the management of established diabetes—each estimation to a maximum of 4 estimations in any 12 month period (SP) | 22.50 |
| 2044 | Glycosylated haemoglobin only when performed in the management of established diabetes—each estimation to a maximum of 4 estimations in any 12 month period (OP) | 17.05 |
| Division 3—Microbiology |
| 2083 | Microscopic examination of material other than blood, from 1 or more sites, obtained directly from a patient and excluding material from cultures—wet film, including differential cell count if performed, examination for dermatophytes or dark ground illumination, or stained preparation or preparations using any relevant stain or stains—1 or more examinations (SP) | 10.00 |
| 2084 | Microscopic examination of material other than blood, from 1 or more sites, obtained directly from a patient and excluding material from cultures—wet film, including differential cell count if performed, examination for dermatophytes or dark ground illumination, or stained preparation or preparations using any relevant stain or stains—1 or more examinations (OP) | 7.55 |
| 2085 | Microscopic examination of faeces for parasites using concentration techniques including the use of appropriate stains, to a maximum of 3 estimations taken on separate days including any service specified in item 2083—each estimation (SP) | 16.80 |
| 2086 | Microscopic examination of faeces for parasites using concentration techniques including the use of appropriate stains, to a maximum of 3 estimations taken on separate days including any service specified in item 2084—each estimation (OP) | 12.70 |
| 2087 | The cultural examination and microscopical examination when indicated (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from nasal swabs, throat swabs, eye swabs and ear swabs, including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2083—1 or more sites (SP) | 26.50 |
| 2088 | The cultural examination and microscopical examination when indicated (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from nasal swabs, throat swabs, eye swabs and ear swabs, including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2084—1 or more sites (OP) | 19.80 |
| Item | Pathology service | Fee |
| | | $ |
| 2089 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic microorganisms, including fungi but excluding viruses, from the following sites—skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens), or specimens of sputum (except when part of item 2119), including pathogenic identification and antibiotic sensitivity testing, including any service specified in item 2083 or 2087—1 or more examinations on 1 or more specimens (SP) | 38.50 |
| 2090 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic microorganisms, including fungi but excluding viruses, from the following sites: skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens), or specimens of sputum (except where part of item 2120), including pathogenic identification and antibiotic sensitivity testing, including any service specified in item 2084 or 2088—1 or more examinations on 1 or more specimens (OP) | 28.95 |
| 2098 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of post-operative wounds, aspirations of body cavities, synovial fluid CSF and operative or biopsy specimens for the presence of pathogenic microorganisms, including fungi but excluding viruses, involving aerobic and anaerobic culture and the use of different culture media and including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2083, 2087 or 2089—1 or more sites (SP) | 52.00 |
| 2099 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of post-operative wounds, aspirations of body cavities, synovial fluid CSF and operative or biopsy specimens for the presence of pathogenic microorganisms, including fungi but excluding viruses, involving aerobic and anaerobic culture and the use of different culture media and including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2084, 2088 or 2090—1 or more sites (OP) | 39.20 |
| 2117 | Cultural examination (including the detection of Clostridial toxins or antigens not elsewhere specified in the Schedule) of faeces to determine the presence or absence of faecal pathogens, involving the use of at least 2 selective or enrichment media as well as culture in at least 2 different atmospheres and including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2083, to a maximum of 3 specimens in any 7 day period—each examination (SP) | 63.00 |
| Item | Pathology service | Fee |
| | | $ |
| 2118 | Cultural examination (including the detection of Clostridial toxins or antigens not elsewhere specified in the Schedule) of faeces to determine the presence or absence of faecal pathogens, involving the use of at least 2 selective or enrichment media as well as culture in at least 2 different atmospheres and including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2084, to a maximum of 3 specimens in any 7 day period—each examination (OP) | 47.50 |
| 2119 | Microscopy with appropriate stains and cultural examinations of 3 specimens of sputum, urine or other bodily fluids for mycobacteria and any other bacterial pathogens, including pathogen identification and antibiotic sensitivity testing and including any service specified in item 2083 (SP) | 89.00 |
| 2120 | Microscopy with appropriate stains and cultural examinations of 3 specimens of sputum, urine or other bodily fluids for mycobacteria and any other bacterial pathogens, including pathogen identification and antibiotic sensitivity testing and including any service specified in item 2084 (OP) | 66.50 |
| 2123 | Blood culture to determine the presence or absence of pathogenic micro-organisms excluding viruses, including serial cultures and sub-cultures, any relevant cultural methods and any tests necessary to identify any cultured pathogen and necessary antibiotic sensitivity testing-each set of cultures to a maximum of 3 sets (SP) | 23.00 |
| 2124 | Blood culture to determine the presence or absence of pathogenic micro-organisms excluding viruses, including serial cultures and sub-cultures, any relevant cultural methods and any tests necessary to identify any cultured pathogen and necessary antibiotic sensitivity testing-each set of cultures to a maximum of 3 sets (OP) | 17.45 |
| 2127 | Urine examination including serial examination, with cell count, relevant stained preparations, culture, colony count by any method, identification of any cultured pathogens, antibiotic sensitivity testing when necessary, and with any relevant general examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts. (Simple culture by dip slide is excluded from this item) (SP) | 28.00 |
| 2128 | Urine examination including serial examination, with cell count, relevant stained preparations, culture, colony count by any method, identification of any cultured pathogens, antibiotic sensitivity testing when necessary, and with any relevant general examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts. (Simple culture by dip slide is excluded from this item) (OP) | 21.00 |
| Item | Pathology service | Fee |
| | | $ |
| 2129 | Direct detection of the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus (in CSF and urine specimens only), RSV, cryptococcal antigens and Varicella zoster or detection of Clostridium difficile toxin except where item 2117 has been performed—1 or more estimations (SP) | 22.00 |
| 2130 | Direct detection of the antigens of Heamophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus (in CSF and urine specimens only), RSV, cryptococcal antigens and Varcella zoster or detection of Clostridium difficile toxin except where item 2118 has been performed—1 or more estimations (OP) | 16.65 |
| 2133 | Direct detection of Chlamydia from clinical material, not cultures—1 or more estimations (SP) | 13.20 |
| 2134 | Direct detection of Chlamydia from clinical material, not cultures—1 or more estimations (OP) | 10.00 |
| 2135 | Direct detection of Herpes simplex from clinical material, not cultures—1 or more estimations (SP) | 13.20 |
| 2136 | Direct detection of Herpes simplex from clinical material, not cultures—1 or more estimations (OP) | 10.00 |
| 2139 | Investigation for Herpes simplex virus (1 or more types) or Chlamydia trachomatis, in material obtained directly from a patient, by 1 or more cultural methods, including any service specified in item 2133 or 2135 (SP) | 38.50 |
| 2140 | Investigation for Herpes simplex virus (1 or more types) or Chlamydia trachomatis, in material obtained directly from a patient, by 1 or more cultural methods, including any service specified in item 2134 or 2136 (OP) | 28.95 |
| 2145 | Serology including IgG and IgM estimations of Rubella, toxoplasma or CMV when performed during pregnancy—1 or more assays (SP) | 18.80 |
| 2146 | Serology including IgG and IgM estimations of Rubella, toxoplasma or CMV when performed during pregnancy—1 or more assays (SP) | 14 10 |
| 2181 | Antibodies to microbial or exogenous antigens not elsewhere specified in the Schedule—estimation of 1 antibody (SP) | 18.80 |
| 2182 | Antibodies to microbial or exogenous antigens not elsewhere specified in the Schedule—estimation of 1 antibody (OP) | 14.10 |
| 2183 | 2 estimations specified in item 2181 (SP) | 29.00 |
| 2184 | 2 estimations specified in item 2182 (OP) | 21.80 |
| 2185 | 3 estimations specified in item 2181 (SP) | 38.50 |
| 2186 | 3 estimations specified in item 2182 (OP) | 28.95 |
| 2187 | 4 estimations specified in item 2181 (SP) | 48.50 |
| 2188 | 4 estimations specified in item 2182 (OP) | 36.40 |
| 2189 | 5 estimations specified in item 2181 (SP) | 59.00 |
| 2190 | 5 estimations specified in item 2182 (OP) | 44.35 |
| 2191 | 6 or more estimations specified in item 2181 (SP) | 69.00 |
| 2192 | 6 or more estimations specified in item 2182 (OP) | 51.45 |
| 2221 | Hepatitis B surface antigen test (SP) | 18.80 |
| Item | Pathology service | Fee |
| | | $ |
| 2222 | Hepatitis B surface antigen test (OP) | 14.10 |
| 2223 | Hepatitis B serology to define the immune status of an individual, including at least Hepatitis B surface antibody or Hepatitis B core antibody tests, including service specified in item 2221, 2229 or 2231 (SP) | 25.35 |
| 2224 | Hepatitis B serology to define the immune status of an individual, including at least Hepatitis B surface antibody or Hepatitis B core antibody tests, including service specified in item 2222, 2230 or 2232 (OP) | 19.00 |
| 2229 | All serological tests performed for the identification of the agent causing acute Hepatitis, which must include Hepatitis B surface antigen, Hepatitis B core antibody and Hepatitis A IgM antibody tests and those service specified in item 2221, 2223 or 2231 (SP) | 50.15 |
| 2230 | All serological tests performed for the identification of the agent causing acute Hepatitis, which must include Hepatitis B surface antigen, Hepatitis B core antibody and Hepatitis A IgM antibody tests and those services specified in item 2222, 2224 or 2232 (OP) | 37.65 |
| 2231 | All tests performed in the follow up of a patient with proven Hepatitis B, including Hepatitis B surface antigen and either Hepatitis Be antigen or Hepatitis B surface antibody tests, including services specified in item 2221 or 2223 (SP) | 36.40 |
| 2232 | All tests performed m the follow up of a patient with proven Hepatitis B, including Hepatitis B surface antigen and either Hepatitis Be antigen or Hepatitis B surface antibody tests, including services specified in item 2222 or 2224 (OP) | 27.35 |
| 2235 | Antibiotics or anti-microbial chemo-therapeutic agents, concentration in serum, urine or other body fluid, by direct quantitative measurement of the agent—1 or more estimations (SP) | 33.25 |
| 2236 | Antibiotics or anti-microbial chemo-therapeutic agents, concentration in serum, urine or other body fluid, by direct quantitative measurement of the agent—1 or more estimations (OP) | 25.00 |
| Division 4—Immunology |
| 2239 | Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1734, 1736 or 2245), on serum, urine or other body fluid, or examination of CSF for oligoclonal proteins by immunoelectrophoresis or immunofixation—1 or more procedures (SP) | 41.15 |
| 2240 | Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1735, 1737 or 2246), on serum, urine or other body fluid, or examination of CSF for oligoclonal proteins by immunoelectrophoresis or immunofixation—1 or more procedures (OP) | 30.90 |
| Item | Pathology service | Fee |
| | | $ |
| 2241 | Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1734, 1736 or 2245) on serum and urine concurrently collected—2 or more procedures (SP) | 61.20 |
| 2242 | Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1735, 1737 or 2246) on serum and urine concurrently collected—2 or more procedures (OP) | 45.90 |
| 2245 | Immunoglobulins G, A, M or D, quantitative estimation in serum, urine or other body fluid, by any method— estimation of 1 immunoglobin (SP) | 20.05 |
| 2246 | Immunoglobulins G, A, M or D, quantitative estimation in serum, urine or other body fluid, by any method— estimation of 1 immunoglobin (OP) | 15.05 |
| 2251 | 2 estimations specified in item 2245 (SP) | 31.15 |
| 2252 | 2 estimations specified in item 2246 (OP) | 23.40 |
| 2253 | 3 or more estimations specified in item 2245 (SP) | 42.20 |
| ??54 | 3 or more estimations specified in item 2246 (OP) | 31.65 |
| 2255 | Subclasses of Immunoglobulin G, 1 to 4, estimation where there is a reduced level of clinical significance of either total IgG or IgA—1 or more estimation (SP) | 61.20 |
| 2256 | Subclasses of Immunoglobulin G, 1 to 4, estimation where there is a reduced level of clinical significance of either total IgG or IgA—1 or more estimation (OP) | 45.90 |
| 2257 | Immunoglobulin E (total), quantitative estimation by any method or methods, with a maximum of 2 estimations in any 12 month period (SP) | 35.35 |
| 2258 | Immunoglobulin E (total), quantitative estimation by any method or methods, with a maximum of 2 estimations in any 12 month period (OP) | 26.60 |
| 2259 | Specific IgG or IgE antibodies to potential allergens—1 or more tests for single or multiple allergens with a maximum of 4 estimations in any 12 month period (SP) | 32.20 |
| 2260 | Specific IgG or IgE antibodies to potential allergens—1 or more tests for single or multiple allergens with a maximum of 4 estimations in any 12 month period (OP) | 24.20 |
| 2261 | Antinuclear antibodies, detection in serum or other body fluids, including quantitation if required (SP) | 33.25 |
| 2262 | Antinuclear antibodies, detection in serum or other body fluids, including quantitation if required (OP) | 25.00 |
| 2263 | Measurment of DNA binding (by Farr or equivalent assay, but excluding the Crithidia method), performed only where a positive antinuclear antibody titre of 1:40 or greater has been obtained (SP) | 40.65 |
| 2266 | Measurement of DNA binding (by Farr or equivalent assay, but excluding the Crithidia method), performed only where a positive antinuclear antibody titre of 1:40 or greater has been obtained (OP) | 30.45 |
| Item | Pathology service | Fee |
| | | $ |
| 2267 | Antibodies to extractable nuclear antigens, detection of in serum or other body fluids (SP) | 28.00 |
| 2268 | Antibodies to extractable nuclear antigens, detection of in serum or other body fluids (OP) | 21.00 |
| 2269 | Characterization of antibodies to extractable nuclear antigens, performed only where a positive result is obtained including services specified in item 2267 (SP) | 44.35 |
| 2270 | Charaterization of antibodies to extractable nuclear antigens, performed only where a positive result is obtained including services specified in item 2268 (OP) | 33.25 |
| 2271 | Antibodies to tissue antigens that are not elsewhere specified in an item in the Schedule—estimation of 1 antibody (SP) | 33.25 |
| 2274 | Antibodies to tissue antigens which are not elsewhere specified in an item in the Schedule—estimation of 1 antibody (OP) | 25.00 |
| 2275 | 2 estimations specified in item 2271 (SP) | 38.55 |
| 2276 | 2 estimations specified in item 2274 (OP) | 28.95 |
| 2277 | 3 estimations specified in item 2271 (SP) | 44.35 |
| 2278 | 3 estimations specified in item 2274 (OP) | 33.25 |
| 2279 | 4 or more estimations specified in item 2271 (SP) | 50.15 |
| 2280 | 4 or more estimations specified in item 2274 (OP) | 37.65 |
| 2281 | Rheumatoid factor, detection of by any technique (SP) | 13.30 |
| 2282 | Rheumatoid factor, detection of by any technique (OP) | 10.00 |
| 2283 | Quantitation of Rheumatoid factor where detected, including services specified in item 2281 (SP) | 26.40 |
| 2284 | Quantitation of Rheumatoid factor where detected, including services specified in item 2282 (OP) | 19.80 |
| 2289 | Complement—total and components—1 quantitative estimation (SP) | 22.20 |
| 2290 | Complement—total and components—1 quantitative estimation (OP) | 16.65 |
| 2291 | 2 estimations as specified in item 2289 (SP) | 33.25 |
| 2292 | 2 estimations as specified in item 2290 (OP) | 25.00 |
| 2293 | 3 or more estimations as specified in item 2289 (SP) | 44.35 |
| 2312 | 3 or more estimations as specified in item 2290 (OP) | 33.25 |
| 2313 | Leucocyte fractionation as a preliminary to leucocyte marker or leucocyte function tests (SP) | 41.15 |
| 2314 | Leucocyte fractionation as a preliminary to leucocyte marker or leucocyte function tests (OP) | 30.90 |
| 2315 | Functional tests for leucocytes, including use of all appropriate techniques (except E. rosette technique or similar) and any test specified in Division 1 — Haematology in the Schedule (SP) | 69.65 |
| 2316 | Functional tests for leucocytes, including use of all appropriate techniques (except E. rosette technique or similar) and any test specified in Division 1 — Haematology in the Schedule (OP) | 52.25 |
| 2317 | Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques to assess lymphoid populations using a minimum of 3 monoclonal antibodies, including any services in item 2319—1 or more estimations (SP) | 88.65 |
| Item | Pathology service | Fee |
| | | $ |
| 2318 | Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques to assess lymphoid populations using a minimum of 3 monoclonal antibodies, including any service in item 2320—1 or more estimations (OP) | 66.50 |
| 2319 | Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques in the investigation of a probable haematological malignancy using a minimum of 7 monoclonal antibodies, including any services in item 2317—1 or more estimations (SP) | 211.00 |
| 2320 | Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques in the investigation of a probable haematological malignancy using a minimum of 7 monoclonal antibodies, including any service in item 2318—1 or more estimations (OP) | 158.25 |
| 2321 | HLA typing comprising A. B. C and DR phenotypes (SP) | 93.90 |
| 2322 | HLA typing comprising A, B, C and DR phenotypes (OP) | 70.45 |
| 2323 | HLA typing, excluding any service specified in item 2321— 1 or more antigens (SP) | 38.55 |
| 2324 | HLA typing, excluding any service specified in item 2322— 1 or more antigens (OP) | 28.95 |
| 2325 | Mantoux test (SP) | 13.30 |
| 2326 | Mantoux test (OP) | 10.00 |
| Division 5—Histopathology |
| 2327 | Histopathology examination of biopsy material including all tissue processing, staining and professional opinion or opinions (SP) | 93.90 |
| 2328 | Histopathology examination of biopsy material including all tissue processing, staining and professional opinion or opinions (OP) | 70.45 |
| 2329 | Immediate frozen section diagnosis of biopsy material, including any other histopathology examination (SP) | 175.15 |
| 2330 | Immediate frozen section diagnosis of biopsy material, including any other histopathology examination (OP) | 131.35 |
| 2331 | Immunohistochemical investigation of biopsy material by one or more of immunofluorescent, immunoperoxidase or other labelled antibody techniques including any other histopathology examination (SP) | 132.95 |
| 2332 | Immunohistochemical investigation of biopsy material by one or more of immunofluorescent, immunoperoxidase or other labelled antibody techniques including any other histopathology examination (OP) | 99.70 |
| 2333 | Electron microscopy of biopsy material including any other histopathology examination (SP) | 141.40 |
| 2337 | Electron microscopy of biopsy material including any other histopathology examination (OP) | 106.05 |
| Division 6—Cytopathology |
| 2338 | Cytological examination of smears from cervix or vagina for detection of pre-cancerous or cancerous changes— 1 or more examinations (SP) | 20.50 |
| Item | Pathology service | Fee |
| | | $ |
| 2339 | Cytological examination of smears from cervix or vagina for detection of pre-cancerous or cancerous changes— 1 or more examinations (OP) | 15.40 |
| 2340 | Cytological examination including serial examinations of smears from skin, nipple discharge, lip, mouth, nose or anus for detection of pre-cancerous or cancerous changes—1 or more examinations (SP) | 20.50 |
| 2341 | Cytological examination including serial examinations of smears from skin, nipple discharge, lip, mouth, nose or anus for detection of pre-cancerous or cancerous changes—1 or more examinations (OP) | 15.40 |
| 2343 | Cytological examination including serial examinations for malignant cells of body fluids, sputum (single specimen), urine (single specimen), washings or brushings not specified in item 2340 and any histopathological service performed on that cytology specimen—1 or more examinations (SP) | 40.10 |
| 2344 | Cytological examination including serial examinations for malignant cells of body fluids, sputum (single specimen), urine (single specimen), washings or brushings not specified in item 2341 and any histopathological service performed on that cytology specimen—1 or more examinations (OP) | 30.10 |
| 2348 | Cytological examination including examination of a series of 3 sputum or urine specimens for malignant cells (SP) | 83.35 |
| 2349 | Cytological examination including examination of a series of 3 sputum or urine specimens for malignant cells (OP) | 62.55 |
| 2350 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues (SP) | 50.15 |
| 2351 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues (OP) | 37.65 |
| 2355 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues where the aspiration is performed by a recognised pathologist or where a recognised pathologist attends the aspiration and performs cytological examination during the attendance (SP) | 93.90 |
| 2356 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues where the aspiration is performed by a recognised pathologist or where a recognised pathologist attends the aspiration and performs cytological examination during the attendance (OP) | 70.45 |
| Division 7—Cytogenetics |
| 2360 | Chromosome studies, including preparation, count and karyotyping of 1 or more of amniotic fluid, bone marrow, skin and any other tissue or fluid excluding blood—1 or more estimations (SP) | 181.50 |
| Item | Pathology service | Fee |
| | | $ |
| 2361 | Chromosome studies, including preparation, count and karyotyping of 1 or more of amniotic fluid, bone marrow, skin and any other tissue or fluid excluding blood—1 or more estimations (OP) | 136.10 |
| 2363 | Chromosome studies, including preparation, count and karyotyping of blood (SP) | 164.60 |
| 2364 | Chromosome studies, including preparation, count and karyotyping of blood (OP) | 123.45 |
| 2365 | Chromosome identification by banding techniques (using fluorescein, Giemsa, or centromere staining or high resolution analysis) or by fragile X-site determination— 1 or more identifications (SP) | 141.40 |
| 2366 | Chromosome identification by banding techniques (using fluorescein, Giemsa, or centromere staining or high resolution analysis) or by fragile X-site determination— 1 or more identifications (OP) | 106.05 |
| Division 8—Infertility and Pregnancy Tests |
| 2370 | Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test) (SP) | 9.30 |
| 2371 | Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test) (OP) | 7.00 |
| 2372 | Semen examination, involving measurement of volume, sperm count, motility, examination of stained preparations, morphology, and, if performed, differential count and 1 or more chemical tests, with a maximum of 4 examinations in any 12 month period (SP) | 38.55 |
| 2373 | Semen examination, involving measurement of volume, sperm count, motility, examination of stained preparations, morphology, and, if performed, differential count and 1 or more chemical tests, with a maximum of 4 examinations in any 12 month period (OP) | 28.95 |
| 2377 | Sperm antibodies, sperm penetrating ability—1 or more tests (SP) | 24.80 |
| 2378 | Sperm antibodies, sperm penetrating ability—1 or more tests (OP) | 18.65 |
| 2379 | Chorionic gonadotrophin (beta—HCG), qualitative estimation in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of pregnancy—1 or more estimations (SP) | 13.55 |
| 2380 | Chorionic gonadotrophin (beta—HCG), qualitative estimation in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of pregnancy—1 or more estimations (OP) | 10.15 |
| 2384 | Chorionic gonadotrophin (beta-HCG), qualitative (if performed) and quantitative estimation in serum by 1 or more methods for diagnosis of hydatidiform mole, HCG—secreting neoplasm, threatened abortion or follow-up of abortion (SP) | 38.55 |
| Item | Pathology service | Fee |
| | | $ |
| 2385 | Chorionic gonadotrophin (beta-HCG), qualitative (if performed) and quantitative estimation in serum by 1 or more methods for diagnosis of hydatidiform mole, HCG—secreting neoplasm, threatened abortion or follow-up of abortion (OP) | 28.95 |
| | Division 9—Simple Basic Pathology Tests | |
| 2387 | Seminal examination for presence of spermatozoa | 6.20 |
| 2389 | Blood count consisting of leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count) or any or all of haemoglobin estimation, haematocrit estimation or erythrocyte count—1 procedure | 4.15 |
| 2390 | 2 procedures specified in item 2389 | 6.20 |
| 2391 | 3 or more procedures specified in item 2389 | 8.25 |
| 2393 | Microscopical examination of urine | 4.15 |
| 2394 | Pregnancy test by 1 or more immunochemical methods | 10.15 |
| 2395 | Microscopical examination of wet film other than urine | 6.20 |
| 2396 | Microscopical examination of gram-stained film | 7.85 |
| 2397 | Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method | 2.10 |
| 2398 | Microscopical examination screening for fungi in skin, hair or nails—1 or more sites | 6.20 |
| 2399 | Mantoux test | 10.15 |
ABBREVIATIONS
A. ABBREVIATIONS FOR GROUPS OF TESTS
| Group | Estimations included in group | Abbreviation | Item numbers |
| Cardiac Enzymes | Lactate dehydrogenase (LDH) Aspartate aminotransferase (AST) and Creatine kinase (CK) | CE | 1562, 1563 |
| Coagulation Studies | Prothrombin Time, activated partial thromboplastin time and 2 or more of the following tests: bleeding time, thrombin clotting time, fibrinogen degradation products, fibrin monomer, D-dimer, Factor XIII screening tests. | COAG | 1527, 1528 |
| Electrolytes | Sodium (NA), Potassium (K), Chloride (CL) and Bicarbonate (HC03) | E | 1564, 1565 |
| Lipid Studies | Cholesterol (CHOL) and Triglycerides (TRIG) | FATS | 1560, 1561 |
| Liver Function Tests | Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) Albumin (ALB), Bilirubin (BIL), Gamma glutamyl transpeptidase (GGT), Lactate dehydrogenase (LDH) and Protein (PROT) | LFT | 1571, 1572 |
| Syphilis Serology | Rapid plasma reagin test (RPR) or venereal disease research laboratory test (VDRL) and Treponema pallidum haemagglutin test (TPHA) or Fluorescent Treponemal antibody-absorption test (FTA) | STS | 2183, 2184 |
B. ABBREVIATIONS FOR INDIVIDUAL TESTS
The abbreviations are listed alphabetically within the following Divisions:
1. HAEMATOLOGY
2. CHEMICAL PATHOLOGY
3. MICROBIOLOGY
4. IMMUNOLOGY
5. HISTOPATHOLOGY
6. CYTOPATHOLOGY
7. CYTOGENETICS
8. INFERTILITY AND PREGNANCY TESTS
| Approved item name of test in Schedule | Abbreviation | Item numbers |
| DIVISION 1—HAEMATOLOGY | | |
| Antithrombin III | ATH | 1531, 1532 |
| Abnormal haemoglobins—spectroscopic examination of blood | AH | 1419, 1420 |
| Bleeding Time | BT | 1521, 1522 |
| Blood coagulation factors—quantitative assays: | | |
| Von Willebrand’s factor antigen | VWA | 1541, 1542 |
| Von Willebrand’s factor | VWF | 1541, 1542 |
| Fletcher Factor | FF | 1541, 1542 |
| Fitzgerald Factor | FGF | 1541, 1542 |
| Passovy Factor | PF | 1541, 1542 |
| Factor II | FII | 1541, 1542 |
| Factor V | FV | 1541, 1542 |
| Factor VII | FVII | 1541, 1542 |
| Factor VIII | FVIII | 1541, 1542 |
| Factor IX | FIX | 1541, 1542 |
| Factor X | FX | 1541, 1542 |
| Factor XI | FXI | 1541, 1542 |
| Factor XII | FXII | 1541, 1542 |
| Factor XIII | XIII | 1541, 1542 |
| Blood Film | BF | 1170, 1171 |
| Blood Group Antibodies | BGA | 1417, 1418 |
| Blood Grouping—ABO and Rh (D antigen) | BG | 1187, 1188 |
| Blood Group and blood group antibodies (group and hold) | BGAB | 1196, 1197 |
| Blood Group Systems (Duffy, Kell, M & N factors, Rh phenotypes) | BGS | 1192, 1193 |
| Bone Marrow Examination—Trephine | BMET | 1181, 1182 |
| Bone Marrow Examination—Aspirate | BMEA | 1183, 1184 |
| Carboxyhaemaglobin | COHB | 1419, 1420 |
| Coagulation Time | CT | 1521, 1522 |
| Cold Agglutinins | CAG | 1419, 1420 |
| Compatibility testing | XMAT | 1198, 1199 |
| C-reactive protein | CRP | 1163, 1164 |
| Differential Cell Count | DIFF | 1170, 1171 |
| Direct Coombs test | CMBS | 1419, 1420 |
| D-dimer test | DD | 1521, 1522 |
| Erythrocyte Count | RCC | 1163, 1164 |
| Erythrocyte Metabolic Enzymes | ERYM | 1176, 1177 |
| Erythrocyte Sedimentation Rate | ESR | 1163, 1164 |
| Erythrocyte Haemolysis | ERYH | 1176, 1177 |
| Euglobulin clot lysis time | ECLT | 1531, 1532 |
| Fibrinogen Degradation Products | FDP | 1521, 1522 |
| Approved item name of test in Schedule | Abbreviation | Item numbers |
| Fibrin Monomer | FM | 1521, 1522 |
| Fibrinogen | FIB | 1521, 1522 |
| Full Blood Examination | FBE | 1172, 1173 |
| Haematocrit | HCT | 1163, 1164 |
| Haemoglobin Estimation | HB | 1163, 1164 |
| Haemoglobinopathy tests | HMGP | 1179, 1180 |
| Heparin Cofactor II | HRNC | 1531, 1532 |
| Heparin Estimation | HEPR | 1539, 1540 |
| Heterophile Antibodies (Infectious Mononucleosis Test) | IM | 1419, 1420 |
| Leucocyte Count | WCC | 1163, 1164 |
| Lupus Anticoagulant | LUPA | 1531, 1532 |
| Metalbumin detection (Schumm’s test) | SCHM | 1419, 1420 |
| Plasminogen | PLAS | 1531, 1532 |
| Partial Thromboplastin Time | PTT | 1521, 1522 |
| Platelet Aggregation | PLTG | 1535, 1538 |
| Platelet Count | PLTC | 1163, 1164 |
| Protein C | PROC | 1531, 1532 |
| Protein S | PROS | 1531, 1532 |
| Prothrombin Time | PT | 1521, 1522 |
| Red Cell Porphyrins—qualitative test | RCP | 1419, 1420 |
| Reticulocyte Count | RETC | 1163, 1164 |
| Test for Factor XIII Deficiency | F13D | 1521, 1522 |
| Thalassaemia Studies | TS | 1179, 1180 |
| Thrombin Time | TT | 1521, 1522 |
| Viscosity of blood or plasma | VISC | 1163, 1164 |
| DIVISION 2—CHEMICAL PATHOLOGY |
| Acetoacetate | ACAT | 1791, 1792 |
| Alanine Aminotransferase | ALT | 1558, 1559 |
| Albumin | ALB | 1558, 1559 |
| Alcohol (Ethanol) | ETOH | 1791, 1792 |
| Alkaline Phosphatase | ALP | 1558, 1559 |
| Alkaline Phosphatase Isoenzymes | ALPI | 1734, 1735 |
| Aminoacids | AMNA | 1791, 1792 |
| Amniotic Fluid Examination | AFE | 1726, 1727 |
| Ammonia | NH3 | 1791, 1792 |
| Amylase | AMS | 1558, 1559 |
| Angiotensin converting enzyme | ACE | 1791, 1792 |
| Aspartate Aminotransferase | AST | 1558, 1559 |
| Beta Hydroxybutyrate | BHYB | 1791, 1792 |
| Bicarbonate | HCO3 | 1558, 1559 |
| Bilirubin (all Fractions) | BILI | 1558, 1559 |
| Bilirubin (Neonatal) | BILN | 1791, 1792 |
| Blood Gases | GAS | 1590, 1591 |
| Breath Hydrogen Test | BHT | 1963, 1964 |
| Calcium (total, dialysed or ionized) | CA | 1558, 1559 |
| Calculus Analysis | CALC | 1595, 1596 |
| Catecholamines | CAT | 1959, 1960 |
| Cholinesterase | CHSE | 1791, 1792 |
| Chloride | CL | 1558, 1559 |
| Cholesterol | CHOL | 1558, 1559 |
| Cystine (Cysteine) | CYST | 1791, 1792 |
| Creatine Kinase | CK | 1558, 1559 |
| Creatine Kinase Isoenzymes | CKI | 1558, 1559 |
| | | |
| Approved item name of test in Schedule | Abbreviation | Item numbers |
| Creatine Kinase Isoenzymes—Quantitative or Qualitative estimation by electrophoresis | CKIE | 1734, 1735 |
| Creatinine | C | 1558, 1559 |
| Cryoglobulins | CGLB | 1575, 1576 |
| Cryofibrinogen | CFIB | 1575, 1576 |
| Drug or Chemical Assays—Overdose | DRGO | 1598, 1599 |
| Drug Assays—Drug abuse treatment programme including urinary drug screen | DRGA | 1627, 1628 |
| Drug Assays—Therapeutic: | | |
| Antibiotics or antimicrobial chemotherapeutic agents (see under MICROBIOLOGY) | | |
| | |
| Amiodarone | AMIO | 1712, 1713 |
| Amitriptyline | AMIT | 1712, 1713 |
| Amylobarb | AMYL | 1712, 1713 |
| Barbitone | BARB | 1712, 1713 |
| Bromide | BRMD | 1712, 1713 |
| Butobarb | BUTO | 1712, 1713 |
| Carbamazepine (Tegretol) | CARB | 1712, 1713 |
| Chloral Hydrate | CHHY | 1712, 1713 |
| Chlorazepate | CHZP | 1712, 1713 |
| Chloropromazine | CHLO | 1712, 1713 |
| Chloroquine | CLOQ | 1712, 1713 |
| Cimetidine | CMTD | 1712, 1713 |
| Clobozam | CLOB | 1712, 1713 |
| Clonazepam (Rivotril) | CLON | 1712, 1713 |
| Cylosporin A | CLSA | 1712, 1713 |
| Desethyl Amiodarone | DEAM | 1712, 1713 |
| Desipramine | DESI | 1712, 1713 |
| Diazepam | DIAZ | 1712, 1713 |
| Digoxin | DIG | 1712, 1713 |
| Diphenylhydantoin (Dilantin) | DIL | 1712, 1713 |
| Disopyramide (Rythmodan) | DISO | 1712, 1713 |
| Doxepin | DOXE | 1712, 1713 |
| Ethosuximide (Zarontin) | ETHO | 1712, 1713 |
| Flecainide | FLEC | 1712, 1713 |
| Hydroxychloriquine | HOCQ | 1712, 1713 |
| Imipramine | IMIP | 1712, 1713 |
| Lignocaine | LIGN | 1712, 1713 |
| Methadone | MTDN | 1712, 1713 |
| Methotrexate | MTTA | 1712, 1713 |
| Methsuximide | MSUX | 1712, 1713 |
| Metronidazole | MRDZ | 1712, 1713 |
| Mexilitine (Mexitil) | MEX | 1712, 1713 |
| N Acetyl Procainamide | NAPC | 1712, 1713 |
| N Desalkyl Clobazan | NDAC | 1712, 1713 |
| N Desalkyldothiepin | NDOT | 1712, 1713 |
| N Desalkyl Doxepin | NDAD | 1712, 1713 |
| Nitrazepam | NITR | 1712, 1713 |
| Nordothiepin | NDIP | 1712, 1713 |
| Nortriptyline | NORT | 1712, 1713 |
| Oxazepam | OXAZ | 1712, 1713 |
| Paracetamol | PARA | 1712, 1713 |
| Paraquat | PARQ | 1712, 1713 |
Approved item name of test in Schedule | Abbreviation | Item numbers |
| Pentabarb | PENT | 1712, 1713 |
| Perhexiline | PHEX | 1712, 1713 |
| Phenobarbitone | PHBA | 1712, 1713 |
| Phensoximide | PHEN | 1712, 1713 |
| Phenytoin | PHEY | 1712, 1713 |
| Prednisolone | PRED | 1712, 1713 |
| Primidone | PRIM | 1712, 1713 |
| Procainamide | PCAM | 1712, 1713 |
| Prominal | PROM | 1712, 1713 |
| Propanolol | PPNO | 1712, 1713 |
| Quinalbarb | QUIB | 1712, 1713 |
| Quinine | QNN | 1712, 1713 |
| Quinidine | QUIN | 1712, 1713 |
| Salicylate-Asprin | SALI | 1712, 1713 |
| Sotalol | SALL | 1712, 1713 |
| Stellazine | STEL | 1712, 1713 |
| Sulphadimidine | SPDD | 1712, 1713 |
| Sulthiame (Ospolot) | SUL | 1712, 1713 |
| Theophylline | THEO | 1712, 1713 |
| Thiopentone | TOPO | 1712, 1713 |
| Thioridazine | THIO | 1712, 1713 |
| Tocainide | TOCN | 1712, 1713 |
| Trimipramine | TRIM | 1712, 1713 |
| Valproate (Epilim) | VALP | 1712, 1713 |
| Vancomycin | VAN | 1712, 1713 |
| Warfarin | WFR | 1712, 1713 |
| Therapeutic drugs that are not listed above must be written in full. | | |
| Electrophoresis | | |
| To demonstrate protein classes or presence and amount of paraprotein classes | EPP1 | 1734, 1735 |
| To demonstrate protein classes or presence and mount of paraprotein classes—concurrent collection | EPP2 | 1736, 1737 |
| | |
| Elements: | | |
| Aluminium | AL | 1871, 1872 |
| Arsenic | AS | 1871, 1872 |
| Beryllium | BE | 1871, 1872 |
| Cadmium | CD | 1871, 1872 |
| Chromium | CR | 1871, 1872 |
| Copper | CU | 1871, 1872 |
| Gold | AU | 1871, 1872 |
| Lead | PB | 1895, 1896 |
| Manganese | MN | 1871, 1872 |
| Mercury | HG | 1871, 1872 |
| Nickel | NI | 1871, 1872 |
| Selenium | SE | 1871, 1872 |
| Strontium | SR | 1871, 1872 |
| Zinc | ZN | 1791, 1792 |
| Enzyme assays of solid tissue or tissues | ENZS | 1969, 1970 |
| Faecal Fat | FFAT | 1963, 1964 |
| Faecal Haemoglobin (chemical test) | FHC | 1577, 1578 |
| Faecal Haemoglobin (immunological test) | FHI | 1579, 1580 |
| Faecal Porphyrins (qualitative test) | FPR | 1577, 1578 |
| | | |
| Approved item name of test in Schedule | Abbreviation | Item numbers |
| Faecal Reducing Substances | FRS | 1577, 1578 |
| Fructosamine | FRUC | 1558, 1559 |
| Gamma Glutamyl Transpeptidase | GGT | 1558, 1559 |
| Globulin | GLOB | 1558, 1559 |
| Glucose | GLUC | 1558, 1559 |
| Glucose Tolerance Test | GTT | 1558, 1559 |
| Glycosylated Haemoglobin (Hb Ale) | GHB | 2043, 2044 |
| HDL Cholesterol | HDLC | 2039, 2040 |
| Hormones: | | |
| Adrenocorticotrophic hormone | ACTH | 2021, 2024 |
| Aldosterone | ALDS | 2021, 2024 |
| Androstenedione | ANDR | 2021, 2024 |
| Arginine | ARIN | 1991, 1992 |
| C-Peptide | CPEP | 2021, 2024 |
| Calcitonin | CALT | 2021, 2024 |
| Cortisol | CORT | 2021, 2024 |
| Cyclic AMP | CAMP | 2021, 2024 |
| Dehydroepiandrosterone sulphate | DHEA | 2021, 2024 |
| Dexamethasone | DXST | 1989, 1990 |
| Dexamethazone Suppression test | DEXA | 2021, 2024 |
| Dihydrotestosterone | DHTS | 2021, 2024 |
| Follicular Stimulating Hormone | FSH | 2021, 2024 |
| Gastrin | GAST | 2021, 2024 |
| Glucagon | GLGO | 2021, 2024 |
| Glucagon—stimulation test | GSTC | 1991, 1992 |
| Gonadotrophin | GRHS | 1991, 1992 |
| Growth Hormone | GH | 2021, 2024 |
| Growth Hormone—exercise | GHSE | 1989, 1990 |
| Growth Hormone—glucose | GHSG | 1989, 1990 |
| Hormone Receptor Assay | HRA | 2037, 2038 |
| Human Placental Lactogen | HPL | 2021, 2024 |
| Hydroxyprogesterone | OHP | 2021, 2024 |
| Insulin | INS | 2021, 2024 |
| Insulin—stimulation test | INHY | 1991, 1992 |
| L-Dopa | GHLD | 1989, 1990 |
| Luteinizing Hormone | LH | 2021, 2024 |
| Oestradiol | E2 | 2021, 2024 |
| Oestriol | E3 | 2021, 2024 |
| Oestrone | E1 | 2021, 2024 |
| Parathyroid Hormone | PTH | 2021, 2024 |
| Pentagastrin | PSTR | 1991, 1992 |
| Progesterone | PROG | 2021, 2024 |
| Prolactin | PROL | 2021, 2024 |
| Renin | REN | 2021, 2024 |
| Secretin | SSGR | 1991, 1992 |
| Sex Hormone Binding Globulin | SHBG | 2021, 2024 |
| Somatomedin | SOMA | 2021, 2024 |
| Testosterone | TES | 2021, 2024 |
| Thyroid Stimulating Hormone | TSH | 2021, 2024 |
| Urine Steroid Fraction or Fractions | USF | 2021, 2024 |
| Vasoactive Intestinal Peptide | VIP | 2021, 2024 |
| Vasopressin | ADH | 2021, 2024 |
| 11 Deoxycortisol | DCOR | 2021, 2024 |
| HIAA (Hydroxyindoleacetic acid) | HIAA | 1791, 1792 |
| Approved item name of test in Schedule | Abbreviation | Item numbers |
| Histamine | HIAM | 1791, 1792 |
| HMMA (Hydroxy Methoxy Mandelic acid previously known as VMA) | HMMA | 1959, 1960 |
| HVA (Homovanillic acid) | HVA | 1959, 1960 |
| Hydroxyproline | HYDP | 1791, 1792 |
| Intestinal disaccharidases | INTD | 1969, 1970 |
| Iron Studies (Iron, Transferrin and Ferritin) | IS | 1752, 1753 |
| Lactate | LACT | 1791, 1792 |
| Lactate Dehydrogenase | LDH | 1558, 1559 |
| Lactate Dehydrogenase Isoenzymes | LDI | 1734, 1735 |
| Lamellar Body Phospholipid | LBPH | 1726, 1727 |
| Lecithin/Sphingomyelin Ratio (Amniotic fluid) | LS | 1726, 1727 |
| Lipase | LIP | 1558, 1559 |
| Lithium | LI | 1558, 1559 |
| Magnesium | MG | 1558, 1559 |
| Metanephrines | MNEP | 1959, 1960 |
| MHPG (Methoxy Hydroxy Phenyethylene Glycol) | MHPG | 1959, 1960 |
| Osmolality, Serum or Urine | OSML | 1583, 1584 |
| Oxalate | OXAL | 1791, 1792 |
| PAA (Phenyl Acetic Acid) | PAA | 1959, 1960 |
| Palmitic acid in amniotic fluid | PALM | 1726, 1727 |
| pH measurement of body fluids other than urine | PH | 1575, 1576 |
| Phosphate | PHOS | 1558, 1559 |
| Phosphatidylglycerol | PTGL | 1726, 1727 |
| Porphyrins (quantitative test, one or more fractions) | PR | 1959, 1960 |
| Potassium | K | 1558, 1559 |
| Prealbumin | PALB | 1738, 1739 |
| Protein (Total) | PROT | 1558, 1559 |
| Protein—Quantitative Estim. of Specific Protein: | | |
| Alpha feto protein | AFP | 1738, 1739 |
| Alpha—1 antitrypsin | AAT | 1738, 1739 |
| Alpha—2 macroglobulin | AMAC | 1738, 1739 |
| Beta-2 microglobulin | BMIC | 1738, 1739 |
| C-l esterase inhibitor | CEI | 1738, 1739 |
| Caeruloplasmin | CPLS | 1738, 1739 |
| Ferritin | FERR | 1738, 1739 |
| Haptoglobins | HGLB | 1738, 1739 |
| Microalbumin | MALB | 1738, 1739 |
| Transferrin | TRAN | 1738, 1739 |
| Pyruvate | PVTE | 1791, 1792 |
| Red Cell Folate and Serum B12 and, if required, Serum Folate | RCF | 1770, 1771 |
| Serotonin | 5HT | 1791, 1792 |
| Serum B12 | B12 | 1768, 1769 |
| Serum Folate | FOL | 1768, 1769 |
| Snake Venom | HISS | 1598, 1599 |
| Sodium | NA | 1558, 1559 |
| Synacthen Stimulation Test | SYNS | 2021, 2024 |
| Thyroid Function Tests | TFT | 1983, 1984 |
| Thyroid Stimulating Hormone (where not requested as part of a TFT) | TSH | 2021, 2024 |
| Thyrotrophin Releasing Hormone Test | TRH | 1985, 1986 |
| Total Free Fatty Acids | TFFA | 1791, 1792 |
| Triglycerides | TRIG | 1558, 1559 |
| Approved item name of test in Schedule | Abbreviation | Item numbers |
| Tumour Markers: | | |
| CA-125 antigen | C125 | 1738, 1739 |
| CA-19.9 antigen | CA19 | 1738, 1739 |
| CA-15.3 antigen | CA15 | 1738, 1739 |
| Carcinoembryonic antigen | CEA | 1738, 1739 |
| Mammary Serum antigen | MSA | 1738, 1739 |
| Mucin-like carcinoma associated antigen | MCA | 1738, 1739 |
| Neuron specific enolase | NSEN | 1738, 1739 |
| Prostate specific antigen | PSA | 1738, 1739 |
| Prostatic acid phosphatase—one or more fractions | ACP | 1738, 1739 |
| SCC related antigen | SCCA | 1738, 1739 |
| Thyroglobulin | TGL | 1738, 1739 |
| Thyrotrophin Releasing Hormone Test | TRH | 1985, 1986 |
| Urate | URAT | 1558, 1559 |
| Urea | U | 1558, 1559 |
| Urine Bilirubin | UBIL | 1575, 1576 |
| Urine Cystine (Cysteine) | UCYS | 1575, 1576 |
| Urine Haemoglobin | UHB | 1575, 1576 |
| Urine Melanin (Melanogen) | UML | 1575, 1576 |
| Urine Myoglobin | UMY | 1575, 1576 |
| Urine Porphobilinogen | UPG | 1575, 1576 |
| Urine Porphyrins (qualitative test) | UPR | 1575, 1576 |
| Urine Urobilinogen | UUB | 1575, 1576 |
| Vitamin D | VITD | 1786, 1787 |
| Vitamin, Quantitative Estimation of Vitamins A, B1, B2, B3, B6, C or E | VIT | 1780, 1783 |
| Xylose | XYL | 1791,1792 |
| DIVISION 3—MICROBIOLOGY | | |
| Antibiotic and antimicrobial chemotherapeutic agents, quantitative assay | QAA | 2235, 2236 |
| Blood Culture | BC | 2123, 2124 |
| Chlamydia Investigation by Cultural Methods | CHLC | 2139, 2140 |
| Clostridium difficile | CLDT | 2129, 2130 |
| CSF antigens—Haemophilus influenzae, Streptococcus pneumoniae, Neisseria menigitidis, Group B Streptococcus | CSFA | 2129, 2130 |
| | |
| Cryptococcal antigen | CRYN | 2129, 2130 |
| Cultural Examination of faeces | FCS | 2117, 2118 |
| Hepatitis Serology: | | |
| Hepatitis Serology in Acute Hepatitis | HEP | 2229, 2230 |
| Hepatitis B Serology in follow up of proven Hepatitis B | HEPB | 2231, 2232 |
| Hepatitis B Surface antigen HBsAg | HBSA | 2221, 2222 |
| Hepatitis B Serology to define immune status | HEPI | 2223, 2224 |
| Herpes simplex Virus Investigation by Cultural Methods | HSVC | 2139, 2140 |
| Microbial Antibody Testing: | | |
| (IgG, IgM, IgA or Total antibodies may be tested against various organisms and are indicated by placing the letter G, M, A and T respectively on the end of the 3 letter abbreviation) | | |
| Actinomycetes | ACT | 2181, 2182 |
| Adenovirus | ADE | 2181, 2182 |
| Aspergillus | ASP | 2181, 2182 |
| Avian precipitins (Bird Fancier’s Disease) | APP | 2181, 2182 |
| Approved item name of test in Schedule | Abbreviation | Item numbers |
| Blastomyces | BLM | 2181, 2182 |
| Bordetella pertussis | BOR | 2181, 2182 |
| Borrelia Berghoffer | BOB | 2181, 2182 |
| Brucella | BRU | 2181, 2182 |
| Campylobacter jejuni | CAM | 2181, 2182 |
| Candida | CAN | 2181, 2182 |
| Chlamydia | CHL | 2181, 2182 |
| Coccidioides | CCC | 2181, 2182 |
| Coxsackie Bl-6 | COX | 2181, 2182 |
| Cryptococcus | CRY | 2181, 2182 |
| Cytomegalovirus | CMV | 2181, 2182 |
| Cytomegalovirus Serology in Pregnancy | CMVP | 2145, 2146 |
| Dengue | DEN | 2181, 2182 |
| Diphtheria | DIP | 2181, 2182 |
| Echinococcus | ECC | 2181, 2182 |
| Echo-coxsackie group | ECH | 2181, 2182 |
| Entamoeba histolytica | AMO | 2181, 2182 |
| Epstein Barr Virus | EBV | 2181, 2182 |
| Fluorescent Treponemal antibody—absorption test (FTA-ABS) | FTA | 2181, 2182 |
| Haemophilus | HUS | 2181 2182 |
| Hepatitis delta antibody—Anti-delta | HDA | 2181 2182 |
| Histoplasma | HIP | 2181 2182 |
| Hydatid | HYD | 2181 2182 |
| Influenza A | FLA | 2181, 2182 |
| Influenza B | FLB | 2181 2182 |
| Legionella pneumophila—Serogroup 1 | LP1 | 2181, 2182 |
| Legionella pneumophila—Serogroup 2 | LP2 | 2181, 2182 |
| Leishmaniasis | LEI | 2181, 2182 |
| Leptospira | LEP | 2181, 2182 |
| Listeria | LIS | 2181, 2182 |
| Measles | MEA | 2181, 2182 |
| Micropolyspora faeni | MIC | 2181, 2182 |
| Mumps | MUM | 2181, 2182 |
| Murray Valley Encephalitis | MVE | 2181, 2182 |
| Mycoplasma pneumoniae | MYC | 2181, 2182 |
| Neisseria gonorrhoea | GON | 2181, 2182 |
| Newcastle Disease | NCD | 2181, 2182 |
| Parainfluenza 1 | PF1 | 2181, 2182 |
| Parainfluenza 2 | PF2 | 2181, 2182 |
| Parainfluenza 3 | PF3 | 2181, 2182 |
| Paratyphi | PTY | 2181, 2182 |
| Pertussis | PER | 2181, 2182 |
| |